HSTO Histogen Inc.

1.65
-0.09  -5%
Previous Close 1.74
Open 1.75
52 Week Low 1.61
52 Week High 7.5
Market Cap $20,143,155
Shares 12,207,973
Float 12,180,103
Enterprise Value $16,130,873
Volume 160,964
Av. Daily Volume 126,125
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
HST 001
Androgenic Alopecia
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020

    SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, has been awarded a $2 million grant by the Peer Reviewed Orthopedic Research Program (PRORP) of the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702, is the awarding and administering acquisition office.

    The Phase 1/2 clinical…

    Investigational New Drug (IND) Filing Expected in the Fourth Quarter of 2020

    SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, has been awarded a $2 million grant by the Peer Reviewed Orthopedic Research Program (PRORP) of the U.S. Department of Defense (DoD) to help fund a Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702, is the awarding and administering acquisition office.

    The Phase 1/2 clinical trial is designed to evaluate HST-003 in combination with a microfracture procedure in 15 civilian and military patients with recent focal cartilage defects in the knee caused by injury. Patients will be enrolled at three clinical sites: OasisMD in San Diego, CA, The Steadman Clinic in Vail, CO and Walter Reed Medical Center in Bethesda, MD. In addition to safety parameters, endpoints will include traditional scores for pain and joint function from The Knee Injury and Osteoarthritis Outcome Scores (KOOS) and The International Knee Documentation Committee (IKDC), as well as an MRI to quantify cartilage regeneration.

    "The Steadman Clinic is world renowned for our dedication to excellence in treating orthopedic defects and we are excited about being a clinical center for studying Histogen's human extracellular matrix, or hECM, for focal lesions of the knee," said Matthew Provencher MD, CAPT, MC, USNR.  "Regenerating uniform functional hyaline cartilage is critical to restoring normal function for military personnel and civilians alike."

    "Lesions in articular knee cartilage can cause considerable morbidity and current surgical options may result in uneven repair and a scar-like fibrous cartilage instead of the normal hyaline cartilage that provides the greatest long-term function," said Dr. Gail K. Naughton, Histogen Founder and CSO. "Histogen's HST-003 has demonstrated hyaline cartilage regeneration in three different in vivo animal models conducted by orthopedic experts. It is an honor to have been granted an award from the DoD to support our HST-003 Phase 1/2 trial," concluded Dr. Naughton.

    There is a significant need for improved acute knee injury treatments in both military and civilian populations. Approximately 900,000 Americans are affected by knee cartilage injuries annually, with 200,000 requiring surgical interventioni. Further, among US military personnel, musculoskeletal injuries are a leading cause of morbidity, lost training time and reduced operational readiness, resulting in as many as 2.4 million health visits and 25 million limited-duty days per yearii.

    "These non-dilutive funds will support our efforts to clinically evaluate the safety and efficacy of our novel cartilage repair treatment which has applicability in both the military and civilian populations," said Richard W. Pascoe, Histogen's President and CEO. "As a former soldier, I understand that the health and readiness of our servicemembers is essential to our national defense. We are pleased to partner with the DoD and these prestigious clinical sites to advance HST-003 into the clinic in support of that effort."

    The views expressed in this press release are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

    About HST-003

    Histogen's human extracellular matrix, or hECM, is intended for regenerating hyaline cartilage for the treatment of articular cartilage defects with a novel malleable scaffold that stimulates the body's own stem cells.  In multiple preclinical models, HST-003 has been shown to regenerate mature cartilage and well vascularized bone, indicating great therapeutic potential in the sports medicine, spinal disc repair, orthopedic, and dental areas. Studies conducted by outside experts have demonstrated that HST-003 is anti-inflammatory, angiogenic, and can stimulate the growth of stem cells in damaged areas to induce tissue regeneration. The most extensive in vivo work in animals has focused on the regeneration of new hyaline cartilage and bone in full thickness knee injuries.

    About Histogen

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Histogen's future operations and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones and related timing, including those related to the planned Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee; the nature, strategy and focus of Histogen's business; and the development and commercial potential and potential benefits of any of Histogen's product candidates. Histogen may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Histogen's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Histogen that could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with the clinical development and regulatory approval of Histogen's product candidates, including potential delays in the commencement, enrollment and completion of clinical trials such as the planned Phase 1/2 clinical trial of HST-003 for regeneration of cartilage in the knee; the potential that earlier clinical trials and studies of Histogen's product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm Histogen's financial condition and increase its costs and expenses; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in Histogen's filings with the Securities and Exchange Commission. Except as otherwise required by law, Histogen disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

    i Merkely, G., Ackermann, J. & Lattermann, C. Articular Cartilage Defects: Incidence, Diagnosis, and Natural History. Oper. Tech. Sports Med. 26, 156–161 (2018).

    ii Teyhen, D. S., Goffar, S. L., Shaffer, S. W., Kiesel, K., Butler, R. J., Tedaldi, A.-M., Prye, J. C., Rhon, D. I. & Plisky, P. J. Incidence of Musculoskeletal Injury in US Army Unit Types: A Prospective Cohort Study. J. Orthop. Sports Phys. Ther. 48, 749–757 (2018).

    CONTACT:

    Susan A. Knudson

    Executive Vice President & CFO

    Histogen, Inc.

    Primary Logo

    View Full Article Hide Full Article
  2. SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced completion of patient dosing for the week 6 treatment timepoint in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

    "We are pleased to have accomplished the second of three treatment timepoints in our HST-001 trial and we remain on track to announce top line data results in the fourth quarter of this year," said Richard W. Pascoe…

    SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO),  a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced completion of patient dosing for the week 6 treatment timepoint in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

    "We are pleased to have accomplished the second of three treatment timepoints in our HST-001 trial and we remain on track to announce top line data results in the fourth quarter of this year," said Richard W. Pascoe, Histogen's President and CEO.  "HST-001, if approved, could be a first-in-class product given its potential to stimulate new long-lasting hair growth in contrast to existing therapies that focus on reducing hair loss."

    About the HST-001 Phase 1a/2b Trial

    This blinded, randomized, placebo controlled, single site study has enrolled 36 subjects with male pattern hair loss using a 2:1 randomization of HST-001 to placebo. It is designed to assess the safety and tolerability of HST-001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography. At each treatment timepoint (Weeks 0, 6 and 12), subjects will receive a total of 20 injections, 10 in the temporal recession region and 5 in each vertex scalp region, the most common areas of hair loss in men with androgenic alopecia.  Primary and secondary endpoints will be assessed at Week 18.  Top-line data is anticipated to be available in the fourth quarter of 2020.

    About HST-001

    HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signaling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

    About Histogen

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.  For more information, please visit www.histogen.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Histogen's future operations and its ability to successfully initiate and complete clinical trials, obtain clinical trial data and achieve regulatory milestones and related timing, including those related to the reporting of topline data for the ongoing HST-001 Phase 1a/2b clinical trial for the treatment of androgenic alopecia in men; the nature, strategy and focus of Histogen's business; and the development and commercial potential and potential benefits of any of Histogen's product candidates, including HST-001. Histogen may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Histogen's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Histogen that could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with the clinical development and regulatory approval of Histogen's product candidates, including potential delays in the commencement, enrollment and completion of clinical trials, such as the reporting of the topline data for the ongoing HST-001 Phase 1a/2b clinical trial for the treatment of androgenic alopecia in men; the potential that earlier clinical trials and studies of Histogen's product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm Histogen's financial condition and increase its costs and expenses; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in Histogen's filings with the Securities and Exchange Commission. Except as otherwise required by law, Histogen disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

    CONTACT:

    Susan A. Knudson

    Executive Vice President & CFO

    Histogen Inc.

    Primary Logo

    View Full Article Hide Full Article
  3. SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the HC Wainwright 22nd Annual Global Investment Conference.  The virtual presentation is scheduled for Tuesday, September 15, 2020 at 11:30 a.m. Eastern Time.

    Presentation Details

    Date: Tuesday September 15, 2020
    Time: 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time)
    Live Webcast Link: https://wsw.com/webcast/hcw7/hsto/1625710

    For those not available to listen to…

    SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the HC Wainwright 22nd Annual Global Investment Conference.  The virtual presentation is scheduled for Tuesday, September 15, 2020 at 11:30 a.m. Eastern Time.

    Presentation Details



    Date: Tuesday September 15, 2020

    Time: 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time)

    Live Webcast Link: https://wsw.com/webcast/hcw7/hsto/1625710

    For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.histogen.com.

    About Histogen Inc.

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

    CONTACT:

    Susan A. Knudson

    Executive Vice President & CFO

    Histogen Inc.

    Primary Logo

    View Full Article Hide Full Article
  4. Completed Enrollment for HST-001 Phase 1a/2b Trial for Androgenic Alopecia in Men with Topline Data Expected 4Q20
    Filed IDE for HST-002 for Treatment of Moderate to Severe Nasolabial Folds
    Appointed Susan A. Knudson as Chief Financial Officer

    SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2020 and provided an update on its clinical pipeline and other corporate developments.

    Key Second Quarter 2020 Highlights and Subsequent Updates

    • Filed Investigational

    Completed Enrollment for HST-001 Phase 1a/2b Trial for Androgenic Alopecia in Men with Topline Data Expected 4Q20

    Filed IDE for HST-002 for Treatment of Moderate to Severe Nasolabial Folds

    Appointed Susan A. Knudson as Chief Financial Officer

    SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2020 and provided an update on its clinical pipeline and other corporate developments.

    Key Second Quarter 2020 Highlights and Subsequent Updates

    • Filed Investigational Device Exemption (IDE) for HST-002. In April, Histogen filed an IDE application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of HST-002 as a dermal filler for the treatment of moderate to severe nasolabial folds. If the application is approved, Histogen plans to initiate the clinical trial in fourth quarter of 2020.

       
    • Closed Reverse Merger with Conatus.  In May, Histogen closed the reverse merger transaction with Conatus.  The transaction included approximately $13.0 million in cash resources, which when combined with existing resources, is expected to fund Histogen's current operating plan into the second quarter of 2021. The combined company changed its name from Conatus Pharmaceuticals Inc. to Histogen Inc. and began trading on the Nasdaq Capital Market under the ticker symbol "HSTO" on May 27, 2020.
    • Appointed Susan A. Knudson as Chief Financial Officer.  In May, Ms. Knudson joined Histogen as its Executive Vice President and Chief Financial Officer.  With over 20 years of experience in the biopharmaceutical industry, she brings a wealth of financial and corporate strategy expertise to Histogen.  Ms. Knudson most recently served as Chief Financial Officer at Pfenex Inc. and prior to Pfenex, she held the position of Chief Financial Officer of Neothetics, Inc. 



    • Completed Enrollment for HST-001 Phase 1a/2b trial for Androgenic Alopecia in Men with Topline Data Expected in the fourth quarter 2020.  Histogen announced that it initiated the trial in June, completed enrollment in July and expects to report topline results in the fourth quarter of 2020.

       
    • Entered into Common Stock Purchase Agreement for Up to $10 Million.  In July, Histogen entered into a common stock purchase agreement for up to $10 million with Lincoln Park Capital Fund, LLC.  Upon execution of the purchase agreement, Lincoln Park made an initial purchase of $1.0 million of common stock.      

    "Throughout the second quarter of this year, we focused on transforming Histogen into a leading restorative therapeutics development company through the completion of the reverse merger, obtaining a NASDAQ listing, strengthening the executive team and advancing our innovative therapeutics pipeline," said Richard W. Pascoe, Histogen's President and Chief Executive Officer.  "In the remaining months of 2020, we will focus on achieving a number of near-term clinical and regulatory value-inflection points, such as filing an IND for our HST-003 program focused on knee cartilage repair, initiating a Phase 1 trial for HST-002 for the treatment of moderate to severe nasolabial folds and reporting topline results from our HST-001 Phase 1a/2b trial for androgenic alopecia in men. Moreover, I want to take this opportunity to commend the entire Histogen team for their tireless efforts, in the midst of a global pandemic, to position the company for success in 2020 and beyond."

    Expected Second Half 2020 Milestones

    • Submit HST-003 IND for the regeneration of cartilage in the knee
    • Initiate HST-002 Phase 1 trial for the treatment of moderate to severe nasolabial folds, if IDE is approved
    • Report topline data for HST-001 Phase 1a/2b trial for androgenic alopecia in men

    Financial Highlights for the Second Quarter 2020

    Revenues for the three months ended June 30, 2020 and 2019 were $0.1 million and $1.4 million, respectively. The year-over-year decrease of $1.3 million was primarily due to a decrease in the fulfillment of supply orders of CCM to Allergan and one additional customer.

    Cost of revenues for the three months ended June 30, 2020 and 2019, were $0 million and $0.5 million, respectively. The decrease of $0.5 million for the three months ended June 30, 2020 as compared to the three months ended June 30, 2019 was due to a decrease in fulfillment of supply orders of CCM to Allergan and one additional customer.

    For both the three months ended June 30, 2020 and 2019, we recognized costs of professional services of $0.1 million related to our Allergan License Agreements.

    In-process research and development expenses for the three months ended June 30, 2020 and 2019 were $7.1 million and $2.3 million, respectively.  In the three months ended June 30, 2020, we incurred $7.1 million for in-process research and development acquired in connection with the reverse merger with Conatus and in the three months ended June 30, 2019, we incurred $2.3 million for in-process research and development related to the acquisition of HST-003 and HST-004  from PUR Biologics LLC.

    Research and development expenses for the three months ended June 30, 2020 and 2019 were $1.4 million and $1.0 million, respectively. The increase of $0.4 million for the three months ended June 30, 2020 was primarily due to an increase in development costs for our  product candidates.

    General and administrative expenses for both the three months ended June 30, 2020 and 2019 were $1.6 million. The three months ended June 30, 2019 included success-based fees of approximately $0.8 million related to $7.5 million of license revenue received in the three months ended June 30, 2019 for which there was no comparable expense incurred in the three months ended June 30, 2020.  This decrease for the three months ended June 30, 2020 was offset by increases in personnel related expenses,  legal and accounting fees in the three months ended June 30, 2020.

    Cash and cash equivalents as of June 30, 2020 were $10.4 million.  Histogen  believes that its existing cash and cash equivalents and cash inflow from operations will be sufficient to meet Histogen's anticipated cash needs into the second quarter of 2021.

    About Histogen Inc.

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Histogen's future operations and its ability to successfully initiate and complete clinical trials, obtain clinical trial data, and achieve regulatory milestones and related timing, including those related to the submission of a HST-003 IND for regeneration of cartilage in the knee, the initiation of a HST-002 Phase 1 trial for the treatment of moderate to severe nasolabial folds and the reporting of topline data for the ongoing HST-001 Phase 1a/2b trial for androgenic alopecia in men; the nature, strategy and focus of Histogen's business; the sufficiency of Histogen's cash resources and Histogen's ability to achieve value for its stockholders; and the development and commercial potential and potential benefits of any of Histogen's product candidates, such as HST-001, HST-002 and HST-003. Histogen may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Histogen's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Histogen that could differ materially from those described in or implied by the statements in this press release, including: the uncertainties associated with the clinical development and regulatory approval of Histogen's product candidates, including potential delays in the commencement, enrollment and completion of clinical trials, such as the planned HST-002 Phase 1 trial for the treatment of moderate to severe nasolabial folds and the reporting of topline data for the ongoing HST-001 Phase 1a/2b trial for androgenic alopecia in men; the potential that earlier clinical trials and studies of Histogen's product candidates may not be predictive of future results; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm Histogen's financial condition and increase its costs and expenses; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including those risks discussed in Histogen's filings with the Securities and Exchange Commission. Except as otherwise required by law, Histogen disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events, or circumstances or otherwise.

    CONTACT:

    Susan A. Knudson

    Executive Vice President & CFO

    Histogen Inc.



    HISTOGEN INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except share and per share amounts)

      June 30,

    2020
      December 31,

    2019
     
      (unaudited)     
    Assets        
    Current assets:        
    Cash and cash equivalents $10,394  $2,065 
    Restricted cash  10   10 
    Accounts receivable, net  136   110 
    Inventories  431   106 
    Prepaid and other current assets  693   167 
    Total current assets  11,664   2,458 
    Restricted cash  250    
    Property and equipment, net  318   320 
    Right-of-use assets  4,468   95 
    Other assets  1,073   69 
    Total assets $17,773  $2,942 
    Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)        
    Current liabilities:        
    Accounts payable $2,659  $808 
    Accrued liabilities  950   446 
    Current portion of lease liabilities  116   108 
    Current portion of deferred revenue  157   19 
    Total current liabilities  3,882   1,381 
    Paycheck Protection Program loan  467    
    Noncurrent portion of lease liabilities  4,666    
    Noncurrent portion of deferred revenue  128   138 
    Other liabilities  317   321 
    Total liabilities  9,460   1,840 
    Commitments and contingencies (Note 10)        
    Convertible preferred stock, $0.001 par value; no shares and 73,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; no shares and 5,046,154 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively; liquidation preference of $0 and $40,294 at June 30, 2020 and December 31, 2019, respectively     39,070 
    Stockholders' Equity (Deficit)        
    Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized at June 30, 2020 and December 31, 2019, respectively; no shares issued and outstanding at June 30, 2020 and December 31, 2019      
    Common stock, $0.0001 par value; 200,000,000 shares and 105,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; 11,812,493 shares and 3,343,356 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively  1    
    Additional paid-in capital  65,176   6,864 
    Accumulated deficit  (55,945)  (43,933)
    Total Histogen Inc. stockholders' equity (deficit)  9,232   (37,069)
    Noncontrolling interest  (919)  (899)
    Total equity (deficit)  8,313   (37,968)
    Total liabilities, convertible preferred stock and stockholders' equity (deficit) $17,773  $2,942 
     
     

    HISTOGEN INC. AND SUBSIDIARIES

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except share and per share amounts)

      Three Months Ended June 30,  Six Months Ended June 30, 
      2020  2019  2020  2019 
    Revenues:                
    License $5  $5  $872  $7,510 
    Product     1,184      1,766 
    Grant     150      150 
    Professional services  103   86   214   153 
    Total revenues  108   1,425   1,086   9,579 
    Operating expenses:                
    Cost of product revenue     513   161   792 
    Cost of professional services revenue  89   75   186   133 
    Acquired in-process research and development  7,144   2,250   7,144   2,250 
    Research and development  1,437   985   2,828   2,043 
    General and administrative  1,588   1,551   2,771   3,405 
    Total operating expenses  10,258   5,374   13,090   8,623 
    Income (loss) from operations  (10,150)  (3,949)  (12,004)  956 
    Other income (expense):                
    Change in fair value of warrant liabilities     25      47 
    Interest income (expense), net  (28)  17   (28)  18 
    Net income (loss)  (10,178)  (3,907)  (12,032)  1,021 
                     
    Net loss attributable to noncontrolling interest  10   8   20   17 
    Net income attributable to preferred stockholders           (624)
    Net income (loss) attributable to common stockholders $(10,168) $(3,899) $(12,012) $414 
    Net income (loss) per share attributable to common stockholders:                
    Basic $(1.52) $(1.17) $(2.39) $0.12 
    Diluted $(1.52) $(1.17) $(2.39) $0.11 
    Weighted-average common shares used to compute net income (loss) per share attributable to common stockholders:                
    Basic  6,710,490   3,327,376   5,026,923   3,321,023 
    Diluted  6,710,490   3,327,376   5,026,923   3,833,835 

     

    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the second quarter ended June 30, 2020 will be released after the close of market on Thursday, August 13, 2020.

    About Histogen Inc.

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned…

    SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the second quarter ended June 30, 2020 will be released after the close of market on Thursday, August 13, 2020.

    About Histogen Inc.

    Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Histogen's innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen's proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

    CONTACT:

    Susan A. Knudson

    Executive Vice President & CFO

    Histogen Inc.

    Primary Logo

    View Full Article Hide Full Article
View All Histogen Inc. News